Santa Clara, CA – 2 May, 2023 – LongeVC, a venture capital firm backing early-stage breakthrough technologies, announced today that it has invested in Melio, a health technology startup pioneering a groundbreaking platform for infectious disease diagnostics.
Doctors often need to prescribe unnecessary and ineffective antibiotics due to limited diagnostic options, spiking the prevalence of antibiotic-resistant superbugs. For infants, early-age antibiotic exposure can lead to a lifetime of ill health. The depth of the problem is immense. For every 150 babies prescribed antibiotics, only one needs them.
Melio’s diagnostics solution rapidly identifies bloodborne pathogens to eliminate unnecessary prescriptions. It evaluates each pathogen cell in a blood sample using AI to analyze how its DNA unwinds, melts, or denatures. By accelerating the diagnostics process, Melio disrupts current inefficient pathogen testing by breaking the “one-pathogen, one-probe” paradigm in diagnostics. It will encourage a healthy start by eliminating the massive overuse of antibiotics at birth and deliver actionable results through its novel testing technology.
Melio’s platform technology is scalable to other disease indications and has the potential to transform the longevity ecosystem with rapid, in-house, and same-day results. Its findings will empower physicians to deliver precise treatment protocols. Melio provides diagnostic capabilities that are scalable “over the air” with universal probes, and no hardware changes are required. Its technology eliminates the time-consuming step of culturing microbes prior to identification, which currently takes three days. The speed and ease of diagnosis will drastically improve the standard of care.
“Diagnostics are an integral component of longevity care,” Garri Zmudze, co-founder and managing partner of LongeVC, said. “Melio’s technology makes it faster and easier for physicians to deliver personalized and effective treatments. We are thrilled to back their game-changing work.”
“Longevity truly starts at day one,” Prof Tzipi Strauss, LongeVC advisory board member and neonatologist said. “Physicians need better ways to diagnose and treat infants. Melio will improve neonatal care and reduce unnecessary antibiotic usage.”
"The investment from LongeVC is a testament to our shared vision for the future of healthcare," said Mridu Sinha, CEO of Melio. "We are committed to making culture-independent pathogen identification accessible to everyone and believe that this partnership will help us achieve our goal of improving health outcomes globally."
Melio is committed to transforming healthcare by delivering rapid and comprehensive diagnostics. LongeVC’s support will empower the company to accelerate platform development, expand clinical research to bring revolutionary healthcare solutions to more people and protect the vulnerable infant population.
Press Contact
LongeVC - Hannah Foster - press@longevc.com
Melio - Mridu Sinha - mridu@melio.tech
About LongeVC
LongeVC is an international venture capital firm investing in visionary biotech companies and founders. Focusing on seed and early-stage investment, LongeVC’s mission is to bring to market breakthrough biotech that will change lives and transform the nature of our health. LongeVC is proud to work with its highly involved and expert advisors, investors and partners to achieve this mission and shape the future of biotech. Learn more about LongeVC portfolio companies and join the fund as an investor at www.longevc.com
About Melio
Melio is a health technology company committed to revolutionizing the healthcare industry by offering rapid diagnostic solutions for bloodstream infections. Through novel DNA melting techniques and AI-driven insights, Melio helps physicians develop actionable treatment plans with culture-independent pathogen detection from blood, reducing hospital costs, testing wait times and over-prescription of antibiotics. By merging cutting-edge molecular biology with innovative AI-driven algorithms, Melio is defining the future of healthcare. Learn more at melio.tech.
Doctors often need to prescribe unnecessary and ineffective antibiotics due to limited diagnostic options, spiking the prevalence of antibiotic-resistant superbugs. For infants, early-age antibiotic exposure can lead to a lifetime of ill health. The depth of the problem is immense. For every 150 babies prescribed antibiotics, only one needs them.
Melio’s diagnostics solution rapidly identifies bloodborne pathogens to eliminate unnecessary prescriptions. It evaluates each pathogen cell in a blood sample using AI to analyze how its DNA unwinds, melts, or denatures. By accelerating the diagnostics process, Melio disrupts current inefficient pathogen testing by breaking the “one-pathogen, one-probe” paradigm in diagnostics. It will encourage a healthy start by eliminating the massive overuse of antibiotics at birth and deliver actionable results through its novel testing technology.
Melio’s platform technology is scalable to other disease indications and has the potential to transform the longevity ecosystem with rapid, in-house, and same-day results. Its findings will empower physicians to deliver precise treatment protocols. Melio provides diagnostic capabilities that are scalable “over the air” with universal probes, and no hardware changes are required. Its technology eliminates the time-consuming step of culturing microbes prior to identification, which currently takes three days. The speed and ease of diagnosis will drastically improve the standard of care.
“Diagnostics are an integral component of longevity care,” Garri Zmudze, co-founder and managing partner of LongeVC, said. “Melio’s technology makes it faster and easier for physicians to deliver personalized and effective treatments. We are thrilled to back their game-changing work.”
“Longevity truly starts at day one,” Prof Tzipi Strauss, LongeVC advisory board member and neonatologist said. “Physicians need better ways to diagnose and treat infants. Melio will improve neonatal care and reduce unnecessary antibiotic usage.”
"The investment from LongeVC is a testament to our shared vision for the future of healthcare," said Mridu Sinha, CEO of Melio. "We are committed to making culture-independent pathogen identification accessible to everyone and believe that this partnership will help us achieve our goal of improving health outcomes globally."
Melio is committed to transforming healthcare by delivering rapid and comprehensive diagnostics. LongeVC’s support will empower the company to accelerate platform development, expand clinical research to bring revolutionary healthcare solutions to more people and protect the vulnerable infant population.
Press Contact
LongeVC - Hannah Foster - press@longevc.com
Melio - Mridu Sinha - mridu@melio.tech
About LongeVC
LongeVC is an international venture capital firm investing in visionary biotech companies and founders. Focusing on seed and early-stage investment, LongeVC’s mission is to bring to market breakthrough biotech that will change lives and transform the nature of our health. LongeVC is proud to work with its highly involved and expert advisors, investors and partners to achieve this mission and shape the future of biotech. Learn more about LongeVC portfolio companies and join the fund as an investor at www.longevc.com
About Melio
Melio is a health technology company committed to revolutionizing the healthcare industry by offering rapid diagnostic solutions for bloodstream infections. Through novel DNA melting techniques and AI-driven insights, Melio helps physicians develop actionable treatment plans with culture-independent pathogen detection from blood, reducing hospital costs, testing wait times and over-prescription of antibiotics. By merging cutting-edge molecular biology with innovative AI-driven algorithms, Melio is defining the future of healthcare. Learn more at melio.tech.